167 related articles for article (PubMed ID: 37986400)
21. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
22. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis.
Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
[TBL] [Abstract][Full Text] [Related]
23. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
24. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
[TBL] [Abstract][Full Text] [Related]
25. Performance of DAXX Immunohistochemistry as a Screen for DAXX Mutations in Pancreatic Neuroendocrine Tumors.
Hechtman JF; Klimstra DS; Nanjangud G; Frosina D; Shia J; Jungbluth AA
Pancreas; 2019 Mar; 48(3):396-399. PubMed ID: 30747827
[TBL] [Abstract][Full Text] [Related]
26. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas.
Gharios J; Hain E; Dohan A; Prat F; Terris B; Bertherat J; Coriat R; Dousset B; Gaujoux S
Best Pract Res Clin Endocrinol Metab; 2019 Oct; 33(5):101294. PubMed ID: 31351817
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.
Ueda H; Akiyama Y; Shimada S; Mogushi K; Serizawa M; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Tanabe M; Tanaka S
Endocr Relat Cancer; 2018 Jun; 25(6):619-631. PubMed ID: 29599123
[TBL] [Abstract][Full Text] [Related]
28. FAM83A promotes the progression and metastasis of human pancreatic neuroendocrine tumors by inducing the epithelial-mesenchymal transition via the PI3K/AKT and ERK pathways.
Zhou B; Zhou X; Zhan C; Jin M; Yan S
J Endocrinol Invest; 2023 Jun; 46(6):1115-1130. PubMed ID: 36344884
[TBL] [Abstract][Full Text] [Related]
29. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
[TBL] [Abstract][Full Text] [Related]
30. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.
Krauss T; Ferrara AM; Links TP; Wellner U; Bancos I; Kvachenyuk A; Villar Gómez de Las Heras K; Yukina MY; Petrov R; Bullivant G; von Duecker L; Jadhav S; Ploeckinger U; Welin S; Schalin-Jäntti C; Gimm O; Pfeifer M; Ngeow J; Hasse-Lazar K; Sansó G; Qi X; Ugurlu MU; Diaz RE; Wohllk N; Peczkowska M; Aberle J; Lourenço DM; Pereira MAA; Fragoso MCBV; Hoff AO; Almeida MQ; Violante AHD; Quidute ARP; Zhang Z; Recasens M; Díaz LR; Kunavisarut T; Wannachalee T; Sirinvaravong S; Jonasch E; Grozinsky-Glasberg S; Fraenkel M; Beltsevich D; Egorov VI; Bausch D; Schott M; Tiling N; Pennelli G; Zschiedrich S; Därr R; Ruf J; Denecke T; Link KH; Zovato S; von Dobschuetz E; Yaremchuk S; Amthauer H; Makay Ö; Patocs A; Walz MK; Huber TB; Seufert J; Hellman P; Kim RH; Kuchinskaya E; Schiavi F; Malinoc A; Reisch N; Jarzab B; Barontini M; Januszewicz A; Shah N; Young WF; Opocher G; Eng C; Neumann HPH; Bausch B
Endocr Relat Cancer; 2018 Sep; 25(9):783-793. PubMed ID: 29748190
[TBL] [Abstract][Full Text] [Related]
31. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
[TBL] [Abstract][Full Text] [Related]
32. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
33. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
Assi HA; Mukherjee S; Kunz PL; Machiorlatti M; Vesely S; Pareek V; Hatoum H
Oncologist; 2020 Feb; 25(2):e276-e283. PubMed ID: 32043766
[TBL] [Abstract][Full Text] [Related]
34. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
Wang WQ; Zhang WH; Gao HL; Huang D; Xu HX; Li S; Li TJ; Xu SS; Li H; Long J; Ye LY; Wu CT; Han X; Wang XH; Liu L; Yu XJ
J Gastroenterol; 2021 Apr; 56(4):395-405. PubMed ID: 33742253
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
Marini F; Giusti F; Brandi ML
Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
[TBL] [Abstract][Full Text] [Related]
36. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
de Wilde RF; Edil BH; Hruban RH; Maitra A
Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
[TBL] [Abstract][Full Text] [Related]
38. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
[TBL] [Abstract][Full Text] [Related]
39. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.
Xu J; Ye Z; Zhuo Q; Gao H; Qin Y; Lou X; Zhang W; Wang F; Wang Y; Jing D; Fan G; Zhang Y; Chen X; Chen J; Xu X; Yu X; Ji S
Cancer Res; 2023 Jul; 83(13):2226-2247. PubMed ID: 36939378
[TBL] [Abstract][Full Text] [Related]
40. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Navale P; Chatterjee D; Itani M; Trikalinos NA
Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
